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Forord 
Denne oppgaven er en del av et stort samarbeidsprosjekt mellom Oslo Universitetssykehus 
(Radiumhospitalet) , Oslo Universitetssykehus (Rikshospitalet) og Det odontologiske 
fakultet, Universitetet i Oslo. Prosjektet har som mål å undersøke senkomplikasjoner hos 
overlevere etter akutt lymfatisk leukemi, malignt lymfom og germinalcelle-cancer behandlet i 
barnealder. Prosjektet har i sin helhet etisk godkjenning av REK [1]. 
Vi presenterer i dette dokumentet en litteraturgjennomgang av maligne lymfomer og hvordan 
disse påvirker munnhulen og dens strukturer, men vårt prosjekt hadde tre ulike faser som 
også inkluderte en klinisk studie: 
1. Første fase var planlegging og utarbeidelse av en prosjektbeskrivelse for 
studentstipendiatsperioden. Dette inkluderte en gjennomgang av litteraturen relatert til 
maligne lymfomer og oral helse spesielt og maligne tilstander generelt. Denne 
litteraturgjennomgangen ble brukt som bakgrunn for det vidre arbeidet i den praktiske 
delen av arbeidet. 
2. Andre fase var praktisk. Vi ble sommeren 2011 tildelt forskningsstipend fra NFR 
knyttet opp mot en praktisk del av prosjektet. Dette arbeidet gikk ut på å måle rot-
krone ratio på premolarer og molarer på 112 OPGer for å undersøke om behandling 
av malignt lymfom i barne- og ungdomsalder påvirker tannutviklingen. Metoden som 
ble valgt er beskrevet av Höllta og medarbeidere i 2004 [2]. Dette viste seg å være et 
svært omfattende og tidkrevende arbeid og det ble dessverre ikke tid til å inkludere 
resultatene fra den praktiske delen i denne oppgaven. Det er en likevel en målsetning 
at noen av de preliminære resultatene vil være klare for presentasjon ved fremføringen 
av oppgaven. Det er også et mål at de bearbeidede resultatene kan inngå i en artikkel 
om oral helse hos langtidsoverlevere etter behandling av malignt lymfom knyttet til 
doktorgradsprosjektet til stipendiat Petter Wilberg. 
3. Tredje fase var bearbeiding av litteraturen og målingene vi hadde gjort. Alle 
målingene fra det praktiske arbeidet ble lagt over i SPSS for analyse. Denne fasen 
inkluderte også utarbeidelsen av dette dokumentet. Det viste seg på slutten at det ikke 
var tid til en presentasjon av den praktiske delen av arbeidet på en måte som kunne 
yte alt arbeidet rettferdighet. Vi valgte derfor å kutte den delen for å konsentrere oss 
om en presentasjon av bakgrunnen for det arbeidet vi har utført. 
Arbeidet er utført av stud. odont. Lobna Ed-Dahbi og Zhenya Draganova (kull H-07). 
Vi ønsker å takke Bente Brokstad Herlofson og Petter Wilberg for all hjelp vi har fått i 
forbindelse med oppgaven vår. 
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Introduction 
Cancer in general 
According to the Cancer register of Norway the number of new cancer cases diagnosed each 
year is rising. In 2009, a total of 27 520 new cases of cancer were recorded in Norway, out of 
which 14 792 occurred in men and 12 728 in women [3].  
Increasing numbers of breast cancer in women, and lung and colorectal cancer in both sexes 
shows a true rise of these types of cancer in the Norwegian population. On the other hand, 
higher cancer incidence may be a result of people living longer or that diagnostic procedures 
in medicine have improved over the last decade [3]. 
Childhood cancer 
Each year, there is between 120 and 150 new cases of childhood cancer in Norway. These 
make up for approximately 0, 6% of all cancer incidence in the population [3]. 
From 01.01.1985 until 31.12.2009 there were 3622 new registered cases of children with 
cancer in Norway. This included children under the age of 15 [4]. 
Malignant lymphoma (ML) is the third most common childhood cancer type in Norway after 
tumors of the CNS and leukemia. It is divided in two forms: Non-Hodgkin`s lymphoma 
(NHL) and  Hodgkin`s lymphoma (HL).  In 2009, 16 out of 780 cases of ML occurred in 
children (12/423 in males and 4/357 in females) [3]. 
Incidence of childhood cancer in Norway for the period 1985-2009 is stable [4]. On the other 
hand, the 10-year-survival rate after cancer treatment in children has increased during the last 
decades to over 80% for patients with Non- Hodgkin`s lymphoma  and over 90% for patients 
with Hodgkin`s lymphoma . There is no significant difference in survival rates between 
different regions in Norway. This indicates that children with cancer receive the same good 
treatment [4]. Nevertheless, new data show a higher risk for late complications in these 
patients than in healthy Norwegians. After cancer treatment they are followed in pediatric 
hospitals departments until they are 18 years, and then at their general medical practitioners 
for the rest of their life as “healthy” cancer survivors [3].  
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Malignant lymphoma 
Classification 
Malignant lymphoma (ML) affects the lymphatic system and is a heterogeneous group of 
diseases which can be classified into 2 main groups:  Hodgkin`s lymphoma (HL) and non- 
Hodgkin`s lymphoma (NHL). They differ in how they behave, spread, and respond to 
treatment [5]. 
Hodgkin`s lymphoma 
HL constitutes 30-40% of all lymphomas. It can be classified in two groups: Classical HL 
and Nodular lymphocyte- predominant HL [6]. 
HL originates from malignant transformation of lymphocytes, most often in B-cells. Typical 
localization for this type of cancer is the lymph nodes and the spleen.  Lymphomas are 
categorized by their size, shape, and growth pattern microscopically [6].  
HL in adults and children share some biological aspects. Reed-Sternberg cells and big 
Hodgkin`s cells are distinctive for the inflammatory environment in HL. They seem to be 
resistant to apoptotic stimuli and are essential for the diagnosis of classical HL [6]. 
Non-Hodgkin`s lymphoma 
NHL accounts for almost 60% of all lymphomas and can be classified as non- B-cell 
lymphoma, B-cell lymphoma, and large cell anaplastic lymphoma [6]. 
NHL is a systemic type of cancer which originates in lymphocytes all over the human body. 
NHL in children is more aggressive and diffuse than NHL in adults. In addition it often 
involves extranodal locations [6]. 
The differences between NHL in adults and children are: 
- Lymphoma in children is a high grade malignant lymphoma. It tends to grow 
sporadic, which means the cancer cells infiltrate the tissue without setting any distinct 
boundaries [6]. 
- A large portion of childhood-lymphoma is initially extra-nodal. This means that 
children lymphomas occur in other sites, apart from lymph nodes, such as in the 
gastro-intestinal tract, tonsils, liver, spleen, thymus, and skeleton. A typical site for 
NHL in the head region is the Waldeyer`s ring [5]. Waldeyer`s ring is:”an 
anathomical term describing the lymphoid tissue ring located in the pharynx and to 
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the back of the oral cavity. The ring consists of pharyngeal tonsil, tubal tonsil, 
palatine tonsils and lingual tonsils” [7]. 
- It is fast- growing and very seldom chronic in children [6]. 
Incidence 
The cancer incidence in Norway has increased since registration of new cases in the Cancer 
register started in 1952. Whereas the incidence of childhood cancer has risen in many 
countries over the last decades, such a rise has not been detected in Norway [3]. 
The incidence of HL shows two peaks in the onset of disease; one in early age and one later 
in life. It is very rare in children under the age of 5, and is affecting boys more often than 
girls. Incidence for NHL increases continuously throughout life and affects boys more often 
than girls [6]. 
Number of new cases by primary site and sex for 2009: 
HL: male -78 female -44 total -122 
NHL: male -483 female -404 total -887 [3] 
Number of new cases by primary site and sex for 2000: 
HL: male -64 female -64 total -128 
NHL: male -385 female -323 total -708 [3] 
Average annual number of new cases by primary site in children of age 0-14 for the period 
2005-2009:  
HL: boys -5 girls -1  total -6 
NHL: boys -5 girls -3  total -8 [3] 
The incidence of malignant lymphoma (ML):  
ML was the 4
th
 most common type of cancer among Norwegian boys between 0-14 years and 
the 6
th
 most common in girls during the period 2005-2009 [3]. 
According to the Cancer Registry males develop malignant lymphoma more often than 
females. There has been a small change in this relationship for HL over the last decades. The 
male/female ratio for HL was 1, 6 for the period 1978-1982 and 1, 4 for the period 2005-
2009. For NHL the male/female ratio was 1, 4 for the period of 1978-1982 and 1, 4 for the 
period of 2005-2009 [3].  
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Etiology 
For most cases of ML the etiology is unknown. It is believed that risk factors for adults can 
be assessed as risk factors for children as well [6]. The most common risk factors are: 
Weakened immune system 
- Individuals with immune defects or undergoing treatment with immunosuppressive 
drugs are proven to be at risk [6] 
- HIV/AIDS patients [6] 
Epstein-Barr virus 
The relationship between the virus and lymphoma is not perfectly clear but in some 
individuals with HL the virus can be detected in big Hodgkin and Reed-Sternberg cells. It is 
unknown how the virus may affect cancer progression. Burkitt`s lymphoma is often 
encountered in Africa in regions severely affected by malaria. It makes up for 50% of all 
childhood cancer in these regions. Malignant cells in these cases are always infected with 
Epstein-Barr virus. It is believed that interaction between chronic malaria infection and 
infection with Epstein-Barr virus can result in formation of a cancer cell. Epstein-Barr virus 
is also believed to play a role in lymphoma formation in immunosuppressed or HIV patients 
[6]. 
Cancer therapy 
NHL has occurred as a secondary cancer after treatment of HL with chemotherapy alone, or 
in combination with radiotherapy. Almost 5% of adults who have been treated for HL 
develop NHL later in life. This risk seems to be lower for children [6]. 
Inheritance 
There is no clear relation between HL and specific genes, even though it seems to be a link 
with some HLA-antigens. There is a statistical data showing almost 50% higher risk of HL in 
children of parents who have had HL [6].   
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Stages 
Staging is important when medical staff have to choose the right treatment and assess the 
prognosis of each patient [8]. 
Hodgkin`s lymphoma  
The Ann Arbor classification is the system most commonly used [8]. 
 
 
 
 
 
Stage 1: Involvement of a single 
LN region or of a single 
extranodal organ or site  
 
Stage 2: Involvement of two or 
more LN regions on the same 
side of the diaphragm, or 
localized involvement of an 
extranodal organ or site 
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Patients can be subdivided into two groups:  
Group A: Patients who do not have general symptoms.  
Group B: Patients that have one or more of the general symptoms: 
- Unaccountable weight loss of over 10% in the last 6 months 
- Unaccountable persistent fever (temperature over 38 grades) for the last 
month 
- Repeated night sweating for the last month [6].  
Stage3:  Involvement of LN regions 
on both sides of the diaphragm 
 
Stage 4: Diffuse or disseminated 
disease in one more extra 
lymphatic organs or tissues with 
or without affection of LN. 
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Non-Hodgkin`s lymphoma 
St. Jude’s staging system for pediatric non-Hodgkin's lymphoma 
Stage I 
 
A single tumor (extranodal) or single anatomic area (nodal) with the 
exclusion of the mediastinum or abdomen 
Stage II 
 
A single tumor (extranodal) with regional node involvement 
Two or more nodal areas on same side of diaphragm 
Two single (extranodal) tumors with or without regional node 
involvement on same side of diaphragm 
A primary gastrointestinal tract tumor, usually in the ileocecal area, 
with or without involvement of associated mesenteric 
nodes only, grossly completely resected 
Stage III 
 
Two single tumors (extranodal) on opposite sides of diaphragm 
Two or more nodal areas above or below diaphragm 
All primary intrathoracic tumors (mediastinal, pleural, and thymic) 
All extensive primary intra-abdominal disease, unresectable 
All paraspinal or epidural tumors, regardless of other tumor sites 
Multifocal bone (now considered stage III rather than IV) 
Stage IV 
 
Any of the above with initial central nervous system and/or bone 
marrow involvement 
Intensity and length of the treatment vary accordingly to stage and prognosis. 
Spreading pattern 
Both HL and NHL are diseases which occur inside the lymphatic system. Lymphomas are 
commonly localized in lymph nodes, thymus, and spleen. Since almost all organs have 
lymphatic tissue, lymphomas can occur almost everywhere in the human body; i.e. in 
intestines, skin, and the skeleton [6]. 
Lymphomas can spread either via the lymphatic or the blood system [6]. 
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Treatment 
Treatment of  NHL and HL depend on type and stage of the lymphoma. Different protocols 
are used. 
Treatment of  HL 
The most widely used protocol in Norway for treating HL is GPOH-HD-95. This is a 
protocol used in an international collaboration study in which Norway participates. The 
protocol, with the latest updates, constitutes the standard treatment of HL in Norway 
nowadays. The treatment of HL is conducted in regional hospitals, or under their supervision. 
It involves chemotherapy for all patients , and post- radiotherapy for most of the patients. 
Patients are stratified in different therapy groups by staging of their disease. Therapy group 1 
is for early stage of the disease, group 2 – for intermediary, and stage 3- for advanced stage of 
the disease [6]. 
Medical treatment: Cytotoxic drugs are used as the main treatment of childhood lymphomas. 
A combination of 4 different cytostatica is the common regime. The most used drugs are 
cyklofosfamid, vinblastin, dakarbazin and bleomycin. They all act by attacking fast dividing 
cells [9]. 
Surgery: Biopsy is a standard procedure for complete typing of the lymphoma. Surgery is 
usually not used for treatment [6]. 
Radiotherapy: Radiotherapy is usually part of the treatment of HL. Total body irradiation is 
usually part of the treatment together and after stem cell transplantation [6].  
In patients with HL, radiotherapy increases the chance for long term survival. However, there 
is a risk for late term complications in children who undergo radiotherapy. These are growth 
disturbances, damage of the irradiated organs and irradiation- based secondary cancer [6].   
Treatment of NHL 
In NHL treatment has improved greatly in the last ten years and there are three main 
treatment protocols.  One of the most important reasons for this improvement  is the use of 
intensive combination of different group of drugs as a primary treatment of the patients. 
Before 1971, only few of the children who received the diagnosis NHL lived for more than 5 
years. All of them had localized disease.  Surgery and radiotherapy was used for treatment of 
stage 1 and 2 patients, but 2/3 of them had relapsed. Today, chemotherapy is the first choice 
of treatment for all types and stages of NHL in children [6]. 
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Surgery: There are a few, uncommon, indications for surgery in NHL, one such is tumor 
affecting the parotid gland [10]. 
Medical treatment: Usually the same cytotoxic drugs as used in the treatment of HL [9]. 
Radiotherapy: Used as a primary treatment of children with NHL in cases when CNS is 
primary affected in non-B cell lymphoma. The amount of absorbed radiation is measured in 
Gray (Gy). Children under the age of 5 in this group receive 18 Gy to the head region. The 
daily dosage is 1, 5 Gy. It is given in 5 fractions per week, until the total dosage is reached 
[6]. 
Survival rates 
The relative survival rate is “a way of comparing survival of people who have a specific 
disease with those who do not. The percentage of survivors is usually determined at specific 
times, such as two years and five years after diagnosis or treatment. The survival rate shows 
whether the disease shortens life” [11]. 
The survival rate for both NHL and HL has been steadily increasing over the last decades. 
The following data about incidence, male/female ratio, and survival rate are extracted from 
the Cancer Register of Norway [3]. 
Hodgkin`s lymphoma: 
 Survival Males (%) Females (%) 
1 year 91,8 93.3 
5 years 88,8 90,6 
10 years 87,0 92,9 
15 years 88,3 90,7 
Non-Hodgkin`s lymphoma: 
Survival Males (%) Females (%) 
1 year 79,2 82,4 
5 years 68,6 71,2 
10 years 61,5 65,8 
15 years 55,2 64,6 
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Relative survival (RS) up to 15 years after diagnosis by sex and age (2007–9): 
Hodgkin`s lymphoma (ICD-10 C81) [3]: 
 
Non-Hodgkin lymphoma (ICD-10 C82–85, C96) [3]: 
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Oral complications 
Anticancer therapy and tooth formation and development 
Anticancer treatment in children is known to cause both acute and chronic longterm oral 
complications. It includes treatment with both radiotherapy and cytotoxic drugs of children 
while tooth formation is ongoing [12]. 
“Acute complications such as mucositis, xerostomia, bleeding, and infections occur three 
times more commonly in children than adults”. “The mouth is been documented as the most 
common source of sepsis in immunosuppressed patients with cancer” [13]. 
Some of the most common complications are foreshortening and blunting of roots, 
incomplete calcification, premature closure of apices, delayed or arrested tooth development, 
and caries [12]. Osteoradionecrosis can occur after extraction or surgery in patients who 
received radiotherapy in head and neck region. The mandible is more prediposed than the 
maxilla [13].  
 
Male long-term Hodgkin`s disease survivor, treated with radiation at the age of 8 years. 
Tooth formation and development 
Tooth development starts between the sixth and eighth week of embryogenesis from 
embryonic cells and can be divided into 4 stages: 
Bud stage: In each dental arch a dental lamina forms along with 10 buds. These 10 buds will 
mature to 10 deciduous teeth. Ectomesenchymal cells surround the bud [14]. 
Cap stage: Each tooth bud grows around an ectomesenchymal aggregation to an enamel 
organ. Dental papilla and dental follicle are other structures you can see at this stage. The 
enamel organ will generate enamel and dental papilla will generate dentin and pulp while the 
dental follicle will generate periodontal structures which support the teeth [14]. 
Bell stage: Bone starts to form. Meckels cartilage is visible. On the periphery of the enamel 
organ you can divide the cells into 4 layers. From outer to inner layer; outer enamel 
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epithelium, stellate reticulum, stratum intermedium and inner enamel epithelium. 
Development of the crown will start at this stage. Other important structures are enamel knots 
and enamel cord [14]. 
Crown stage: Hard tissue like crown and dentin starts forming [14]. 
Amelogenesis 
It starts during the late bell stage. The enamel formation goes through a secretory stage and a 
maturation stage [14]. 
Mesenchymal cells differentiate to odontoblasts (OB) which produce predentin. When 
predentin undergoes mineralization, cells in the inner enamel epithelium will transform to 
ameloblasts which produce enamel. The ameloblasts are found close to the cusps of teeth. 
The ameloblasts will start producing organic (proteins) and inorganic (hydroxyapatite) 
materials and move toward the outer enamel epithelial layer [14]. 
Dentinogenesis 
There are 4 phases in dentin formation: 
Odontoblast differentiation: The OBs precursors are called pre- odontoblasts. When pre-obs 
receive the right signals from the surroundings they start growing longer, their nucleus moves 
to the basal side of the cell, away from the enamel layer. The cell gets an appearance of a 
typical secretory cell. OBs grow processes which point towards the basal lamina [14]. 
Matrix secretion: Dentin matrix is made mainly of collagen type I, phosphoproteins (DPP- 
dentinphosphoprotein; DSP- dentin sialoprotein), proteoglycans, and glycoproteins. The cells 
producing it are mature OBs [14]. 
Predentine (immature dentin) is formed by deposition of collagen type I by OBs while the 
cell is moving away from the basal lamina and towards the dental papilla.  
Dentine mineralization: Conducted by proteins which are seen only in dentin, and no other 
tissue in the human body [14] 
Root dentin formation: Root dentin is secreted by OB differentiated from Hertwig`s root 
epithelium (HRE). The collagen fibers are laid down parallel to the cement-dentine junction 
[14]. 
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Adverse effects of anticancer treatment on tooth development 
Anticancer treatment of children is known to cause oral complications. Mineralization of 
permanent teeth is a process which starts soon after birth and takes around 15 years if not 
counting the wisdom teeth.   
 
Table which shows chronology and mineralization of primary and permanent teeth. [15]. 
Root formation starts after crown formation is ended. First molars and incisors in the upper 
jaw are the first to start root formation. Second molars are last with root formation starting 
around the age of 7, 5. Trauma in generel can disturb this process. Since root formation is a 
slow process, changes on panoramic radiographs can be detected from one to two years after 
the actual trauma. Unlike other mineralized tissues in the body, teeth cannot remodel and 
disturbances in their structure are therefore permanent [12]. 
Depending on the dental age and what kind of treatment the patient has received, the effect 
on different teeth can vary. The same treatment can cause microdontia and/or agenesis in 
young age, and disturbed root formation later in life.  The full impact of anticancer treatment 
on tooth formation is therefore not fully seen before root formation is ended. This usually 
happens a few years after the end of treatment [12]. 
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Dental growth disturbances in two long-term survivors treated with cytotoxic drugs for acute lymphatic 
leukemia and is included in an ongoing multidisciplinary PhD-study on long term adverse effects of cancer 
treatment during childhood and adolescence (Wilberg P, Herlofson BB). A) Microdontia of tooth 37 (also 47) in 
a 30 year old man treated at the age of 2-3. B) Mineralization disturbances on several teeth in an 18 year old 
man treated from 2,5 years of age and in three periods [16]. 
 
Important factors affecting root formation, are type of drug, dosage and if radiation has been 
given. Anticancer drugs have lethal effect on tooth forming cells [12]. High doses of a 
chemotherapeutic drug can give necrosis, whereas smaller doses can induce cells to undergo 
apoptosis [17]. 
Signal exchange between ectomesenchyme and dentine epithelium is essential for early tooth 
formation. Everything that can disturb this process, cause cell death or metabolic disturbances 
in one or both layers, can affect tooth formation as well [12]. Anticancer treatment can affect 
root formation either directly or indirectly. Death of the root forming cells is a direct effect of 
the treatment. Disturbance in signalization between both layers is an indirect effect [15]. The 
effect of anticancer treatment is more detrimental when total body irradiation (TBI) is used 
combined with high dose chemotherapy (HDC) than when HDC is used alone [12]. 
HDC alone can affect tooth formation. Höllta and co-workers [12] found indications of this, 
but concluded that they could not reliably estimate HDC’s influence on root formation 
completely due to the study being conducted before complete root formation in several of the 
study subjects [12]. 
The most detrimental effects of anticancer treatment, with no respect to TBI being used or 
not, are seen in children at age 3, 1-5 years. Fast deviding cells are most affected.  At this age 
crown formation is over and root formation has started. The cells of HRE are the fastest 
deviding cells in teeth at this time. If anticancer treatment is finished before the age of three, 
HRE cells have not differentiated and would therefore be more resistant to the drugs. The 
negative effect of the treatment would be weaker as well if the treatment starts after the age 
of five since root formation would have started. Most teeth affected in this scenario would be 
second premolars and second molars since their root mineralization starts later [12]. 
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Chemotherapeutic agents are also known to cause nerve damage to sensory or motor nerves 
[18].  Dental pain during anticancer treatment can be the result of drug induced neurotoxicity 
[19]. Radiation therapy to the head and neck region is known to cause xerostomia, radiation 
induced caries, and taste alterations to patients with Hodgkin`s disease [20]. 
Summary 
Malignant lymphomas are among the most common types of cancer in children and 
adolecents. Recent advances in the treatment of these malignancies in children have resulted 
in more long term survivors (LTSs) of these types of cancer. This has also resulted in many 
LTSs experiencing late adverse effects due to the disease and/or its treatment that was 
previously unknown, among others; adverse effects influencing oral health.  
The LTSs can expect to live long, and some of the adverse effects in the oral cavity can pose 
a significant challenge to the survivors and oral health professionals in the future. More 
research is needed to determine the incidence and prevalence of adverse effects in the oral 
cavity in cancer and cancer treatment and the possible economic impact they can pose for the 
LTSs and the government. 
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